Drozitumab is a human monoclonal antibody in development for the treatment of cancers.[1][2] It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.[3][4] Drozitumab was developed by Genentech.

Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.[3]

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab" (PDF). American Medical Association.
  2. ^ Micheau O, Shirley S, Dufour F (August 2013). "Death receptors as targets in cancer". British Journal of Pharmacology. 169 (8): 1723–1744. doi:10.1111/bph.12238. PMC 3753832. PMID 23638798.
  3. ^ a b "Drozitumab". AdisInsight. Retrieved 31 January 2017.
  4. ^ Gasparini C, Vecchi Brumatti L, Monasta L, Zauli G (2013). "TRAIL-based therapeutic approaches for the treatment of pediatric malignancies". Current Medicinal Chemistry. 20 (17): 2254–2271. doi:10.2174/0929867311320170009. PMID 23458616.


No tags for this post.